viewCannPal Animal Therapeutics Ltd

CannPal Animal Therapeutics caps off busy September quarter

The company had a healthy cash balance of $4.72 million at the end of the quarter.

dog with cannabis leaf
The company is researching the benefits of medical cannabis for dogs and cats

CannPal Animal Therapeutics Ltd (ASX:CP1) has had a busy September quarter entering two research agreements and advancing its lead cannabis-derived drug candidate CPAT-01.

CPAT-01D, a pain treatment for dogs, received ethics approvals and the CPAT-01 development program was expanded to include cats CPAT-01C.

The phase Ib study for CPAT-01D has commenced and is expected to be completed this December quarter.

READ: CannPal Animal Therapeutics commences dog pain control study

CannPal's managing director Layton Mills said: “This has been another important quarter for CannPal with some significant milestones.

“Our additional research agreements are further validation of the high-quality research we are undertaking in our mission to develop cannabis-derived treatments for companion animals.

“In addition, the rapid progression of our clinical studies and development of our nutraceutical pipeline underscore our commitment to delivering value to our shareholders.”

Solid end-of-quarter cash balance

CannPal had a cash balance of $4.72 million in line with its budget forecasts and sufficient to continue with its research and development activities in the coming months.

READ: CannPal Animal Therapeutics director shows confidence in company’s cannabis-derived animal medications

Earlier this month, director Max Johnston demonstrated his confidence in the company’s cannabis-derived medications for animals by acquiring shares on-market.

Johnston, a non-executive director, acquired almost 64,400 shares with a total value of more than $9,000.

Quick facts: CannPal Animal Therapeutics Ltd

Price: 0.12 AUD

Market: ASX
Market Cap: $11.18 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CannPal Animal Therapeutics Ltd named herein, including the promotion by the Company of CannPal Animal Therapeutics Ltd in any Content on the...



CannPal Animal Therapeutics leveraged to 'lucrative potential' of growing market

CannPal Animal Therapeutics Ltd (ASX:CP1) founder and managing director Layton Mills speaks to Proactive Investors about the innovative pet pharmaceutical company, which operates in the medical cannabis space. "The goal for the company is really to develop products that can address clear,...

on 25/6/18

2 min read